Ziosoft is taking the opportunity at RSNA 2020 to show how its vendor-neutral 3D/4D visualization software is helpful for visualizing damage to the heart and other organs from COVID-19.
Applications on the company's Ziostation2 workstation help assess cardiovascular, respiratory, and pulmonary pathology, Ziosoft said. While the novel coronavirus was initially thought to be primarily a respiratory illness, conditions in other parts of the body, such as the brain and heart, have since come to the fore. Up to 24% of COVID-19 patients actually get myocardial injury or heart failure, the company noted.
Tools available for making the diagnosis include virtual bronchoscopy, CT cardiac function, and MR coronary analysis, Ziosoft said.
